Industry Briefs: Apr. 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 30, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI has launched Smartsourcing sourcing options for its contract manufacturing and research services. Read More

AstraZeneca and The Medicines Company have entered into a global development and commercialization pact and have agreed to copromote Brilinta (ticagrelor), for treating acute ischaemic heart disease, in the United States. Read More

Baxter International has completed its purchase of Sigma International. Read More

Cetero Research has reached a final resolution with FDA over studies the company conducted in its Houston, Texas, bioanalytical laboratory between Apr. 1, 2005 through June 15, 2010. Read More

Covance and BML are expanding the companies’ jointly owned clinical-trial laboratory in Japan. Read More

GlaxoSmithKline and the University of Nottingham are collaborating to create a Center of Excellence for sustainable chemistry. Read More

Penn Pharma has invested in additional clinical and commercial packing capabilities. Read More

Teva has settled its patent-infringement litigation with Mylan in regards to Teva’s wakefulness product Nuvigil (armodafinil). Read More

Therapure has opened a custom biologics manufacturing facility. Read More

People News

AMRI has appointed Saravanakumar Dhakshinamoorthy as director of in vitro biology. Dhakshinamoorthy will report to Takeshi Yura, senior director of AMRI’s Singapore division. Read More

Watson Pharmaceuticals has announced changes in the company’s senior leadership. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here